These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26944462)

  • 21. The use of estrogen therapy in women's sexual functioning (CME).
    Nappi RE; Polatti F
    J Sex Med; 2009 Mar; 6(3):603-16; quiz 618-9. PubMed ID: 19284468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone Therapy and Other Treatments for Symptoms of Menopause.
    Hill DA; Crider M; Hill SR
    Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel
    Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
    Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
    J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial.
    Fernandes T; Costa-Paiva LH; Pinto-Neto AM
    J Sex Med; 2014 May; 11(5):1262-70. PubMed ID: 24612478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and impact of vaginal symptoms among postmenopausal women.
    Santoro N; Komi J
    J Sex Med; 2009 Aug; 6(8):2133-42. PubMed ID: 19493278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
    Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
    Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
    Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
    J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women.
    Santen RJ; Kagan R; Altomare CJ; Komm B; Mirkin S; Taylor HS
    J Clin Endocrinol Metab; 2014 Mar; 99(3):733-47. PubMed ID: 24423357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Oxytocin Vaginal Gel on Sexual Function in Postmenopausal Women: A Randomized Controlled Trial.
    Abedi P; Zohrabi I; Ansari S; Maraghi E; Maram NS; Houshmand G
    J Sex Marital Ther; 2020; 46(4):377-384. PubMed ID: 32169019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick?
    Ewies AA; Alfhaily F
    Climacteric; 2010 Oct; 13(5):405-18. PubMed ID: 20670198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
    Eder SE
    Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ospemifene, vulvovaginal atrophy, and breast cancer.
    Wurz GT; Soe LH; DeGregorio MW
    Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of the genitourinary syndrome of menopause.
    Palacios S; Mejía A; Neyro JL
    Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.